G Schleiermacher

Summary

Affiliation: Institut Curie
Country: France

Publications

  1. pmc Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)
    G Schleiermacher
    , Institut Curie, 26 rued Ulm, 75248 Paris Cedex 05, France
    Br J Cancer 89:470-6. 2003
  2. pmc Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
    G Schleiermacher
    INSERM U830, Institut Curie, Paris, France
    Br J Cancer 97:238-46. 2007
  3. pmc Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour
    J Vermeulen
    Département d oncologie pédiatrique, Institut Curie, Paris, France
    Br J Cancer 95:1326-33. 2006
  4. pmc Learning smoothing models of copy number profiles using breakpoint annotations
    Toby Dylan Hocking
    INRIA Sierra project team, Paris F 75013, France
    BMC Bioinformatics 14:164. 2013
  5. pmc Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
    G Schleiermacher
    INSERM U, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France
    Br J Cancer 107:1418-22. 2012
  6. pmc Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
    G Schleiermacher
    INSERM U830, Laboratoire de Génétique et Biologie des Cancers, 26 Rue d Ulm, Paris Cedex 05, France
    Br J Cancer 105:1940-8. 2011
  7. ncbi request reprint CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases
    S Brisset
    , INSERM U509, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Cedex 05, Paris, France
    Cancer Genet Cytogenet 130:57-61. 2001
  8. doi request reprint Molecular pathogenesis of peripheral neuroblastic tumors
    I Janoueix-Lerosey
    INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris Cedex 05, France
    Oncogene 29:1566-79. 2010
  9. doi request reprint Malformations, genetic abnormalities, and Wilms tumor
    S Dumoucel
    Department of Pediatric Oncology, Institut Curie, Paris, France
    Pediatr Blood Cancer 61:140-4. 2014
  10. ncbi request reprint [Detection of micrometastases and circulating tumour cells using molecular biology technics in solid tumours]
    G Schleiermacher
    Inserm U.509, , Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05
    Bull Cancer 88:561-70. 2001

Collaborators

Detail Information

Publications10

  1. pmc Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)
    G Schleiermacher
    , Institut Curie, 26 rued Ulm, 75248 Paris Cedex 05, France
    Br J Cancer 89:470-6. 2003
    ..005). The clinical evolution observed with the different successive treatment approaches suggests that if infants do require therapy, the prompt initiation of a more intensive regimen such as carboplatin-etoposide may be more beneficial...
  2. pmc Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
    G Schleiermacher
    INSERM U830, Institut Curie, Paris, France
    Br J Cancer 97:238-46. 2007
    ..Further studies using higher-resolution CGH are needed to better characterise atypical genomic alterations...
  3. pmc Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour
    J Vermeulen
    Département d oncologie pédiatrique, Institut Curie, Paris, France
    Br J Cancer 95:1326-33. 2006
    ..Tumour cell contamination of PBSC collection is rare and does not seem to be associated with a significantly poorer EFS or OS in this high-risk population...
  4. pmc Learning smoothing models of copy number profiles using breakpoint annotations
    Toby Dylan Hocking
    INRIA Sierra project team, Paris F 75013, France
    BMC Bioinformatics 14:164. 2013
    ..Furthermore, most methods have a smoothing parameter that determines the number of breakpoints and must be chosen using various heuristics...
  5. pmc Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
    G Schleiermacher
    INSERM U, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France
    Br J Cancer 107:1418-22. 2012
    ..In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested...
  6. pmc Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
    G Schleiermacher
    INSERM U830, Laboratoire de Génétique et Biologie des Cancers, 26 Rue d Ulm, Paris Cedex 05, France
    Br J Cancer 105:1940-8. 2011
    ..In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse...
  7. ncbi request reprint CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases
    S Brisset
    , INSERM U509, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Cedex 05, Paris, France
    Cancer Genet Cytogenet 130:57-61. 2001
    ....
  8. doi request reprint Molecular pathogenesis of peripheral neuroblastic tumors
    I Janoueix-Lerosey
    INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris Cedex 05, France
    Oncogene 29:1566-79. 2010
    ..Finally, based on recent observations integrating genomic analyses, biological data and clinical information, we discuss possible evolution/progression schemes in NB...
  9. doi request reprint Malformations, genetic abnormalities, and Wilms tumor
    S Dumoucel
    Department of Pediatric Oncology, Institut Curie, Paris, France
    Pediatr Blood Cancer 61:140-4. 2014
    ..This study aims to describe clinical malformations, genetic abnormalities, and tumor predisposition syndromes in patients with WT and to propose guidelines regarding indications for clinical and molecular genetic explorations...
  10. ncbi request reprint [Detection of micrometastases and circulating tumour cells using molecular biology technics in solid tumours]
    G Schleiermacher
    Inserm U.509, , Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05
    Bull Cancer 88:561-70. 2001
    ..However, results of studies performed on larger series of patients together with a better standardization of technics are necessary before they can be used for individual staging of patients...